INOC is currently conducting over 200 clinical trials registered on international platforms, ranging from interventional studies, across various stages of drug development, to nursing and surgical studies. Among the areas of greatest innovation are: cell therapies and CAR-T therapies, cancer vaccines, oncolytic viruses, bispecific antibodies, antibody-drug conjugates, and molecularly targeted therapies.
To support this research, INOC’s advanced molecular diagnostics service is capable, for certain clinical cases, of analyzing over 500 genetic variants associated with more than 28 types of cancer, enabling precise guidance in treatment selection and facilitating access to targeted clinical trials.
Use the search engine to find active clinical trials and see if there are any opportunities to participate that are suitable for your medical condition.
Phase I open-label, dose escalation trial of BI 1831169 monotherapy and in combination with an anti-PD-1 mAb in patients with advanced or metastatic solid tumors.
Diseases: Gastrointestinal tumor (GI tumor), Head and neck cancers, Melanoma, Pancreatic cancer
Medication: BI 1831169 (VSV-GP)
BI 754091 (Ezabenlimab; anti-PD-1 mAb)
FASE I
A Phase 1, multicenter, open-label, non-randomized, dose-escalation study with backfill cohorts of KK2223 in participants with relapsed or refractory T-cell non-Hodgkin lymphoma.
Diseases: Onco-hematological (hematological cancers/malignancies)
Medication: KK2223 (anti-CCR4 ADC)
FASE I
A Phase 3, Double-Blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) for the first-line treatment of locally advanced, unresectable, or metastatic gastric or gastroesophageal adenocarcinoma in participants whose tumors are HER2-negative, Claudin (CLDN) 18.2-positive, and whose combined positive scores (CPS) are greater than or equal to 1.
Diseases: Gastrointestinal tumor (GI tumor)
Medication: Zolbetuximab in combination with pembrolizumab + (CAPOX or mFOLFOX6)
FASE III
A Phase 2/3, open-label, randomized study of telisotuzumab adizutecan compared with standard of care in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with an EGFR mutation, following progression on a third-generation TKI.
Diseases: Lung Cancer
Medication: Osimertinib
, Telisotuzumab Adizutecan
FASE II
A multimodal approach in patients with mHSPC. A pragmatic randomized trial of Apalutamide plus androgen deprivation therapy (ADT).
Diseases: Male urologic cancers (urological tumors)
Medication: Apalutamide + local treatment in hormone-sensitive metastatic prostate cancer.
FASE III
A global, randomized, double-blind, multicenter Phase III study of Rilvegostomig or Pembrolizumab in combination with platinum-based chemotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (D702BC00001).
Diseases: Lung Cancer
Medication: Rilvegostomig
, Pembrolizumab
FASE III
A Phase 1 study, first in human, of ARV-393 in adult participants with advanced-stage non-Hodgkin lymphoma.
Diseases: Onco-hematological (hematological cancers/malignancies)
Medication: ARV-393 (BCL6 transcriptional factor inhibitor)
Glofitamab
Obinutuzumab
FASE I (FIH)
Phase II study of Axitinib intensification in combination with Nivolumab versus Nivolumab alone, following induction with Nivolumab plus Ipilimumab, in patients with metastatic renal cell carcinoma (mRCC) without a previous complete response.
Diseases: Kidney cancer (renal cancer)
Medication: Axitinib in combination with nivolumab or nivolumab alone
FASE II
A multicentre, randomised, open label Phase Ib dose escalation and Phase II dose optimisation study of oral Zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2 positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or oesophageal adenocarcinoma (mGEAC).
Diseases: Breast Cancer, Gastrointestinal tumor (GI tumor)
Medication: Oral zongertinib (BI 1810631) alone or in combination with other standard therapeutic agents.
FASE II
A Phase 3, multicenter, randomized, open-label study designed to evaluate Mocertatug Rezetecan in combination with Bevacizumab compared with a platinum-based doublet regimen in combination with Bevacizumab in participants with platinum-sensitive ovarian cancer.
Diseases: Gynecologic cancers (gynecological tumors)
Medication: Mocertatug Rezetecan + Bevacizumab vs. Platinum Doublet + Bevacizumab.
FASE III